Aligos Therapeutics (ALGS) AI Stock Analysis

• Market Cap: $44.64M
• Dividend Yield: N/A
• Average Volume (3M): 159.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.76
• Revenue Growth: -76.29%
• EPS Growth: N/A
• Country: US
• Employees: 70
• Sector: Healthcare
• Sector Strength: 55
• Industry: Biotechnology
• EPS (TTM): -2.11
• Shares Outstanding: 5,314,801
• 10 Day Avg. Volume: 165,172
• 30 Day Avg. Volume: 159,694
• PEG Ratio: 0.35
• Price to Book (P/B): 9.79
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -12.66
• Enterprise Value/Market Cap: 21.24
• Enterprise Value/Revenue: 44.77
• Enterprise Value/Gross Profit: 476.74
• Enterprise Value/Ebitda: -2.64
• 1Y Price Target: $53.00
• Price Target Upside: 571.74% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 53 Neutral
• Price Target: $8.00 ▲(1.39%Upside)

Aligos Therapeutics' stock score is primarily influenced by its financial challenges and early-stage operational characteristics. While technical analysis indicates positive momentum, the financial risks and valuation concerns due to the lack of profitability are significant detractors.

Positive Factors

Clinical Trials

The initiation of ALG-000184's randomized, double-blind, active-controlled Phase 2 study is regarded as Aligos' next major milestone.

Therapeutic Potential

ALG-000184 showcased robust and sustained antiviral activity in both HBeAg-positive and HBeAg-negative patients with CHB, highlighting its potential as a first-line therapy for long-term viral suppression.

Negative Factors

Market Competition

ALG-000184 achieved the primary endpoint in 100% of patients in the Phase 1 study, compared to 21% for the standard-of-care treatment.

Safety Concerns

ALG-000184 showed a favorable safety profile, with no viral breakthroughs or known CAM-resistant mutations reported with ALG-000184 monotherapy treatment.

Aligos Therapeutics Business Overview & Revenue Model

Company Description

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

How the Company Makes Money

Aligos Therapeutics generates revenue primarily through research and development partnerships, licensing agreements, and collaboration with other pharmaceutical companies. These partnerships often involve upfront payments, milestone payments based on the achievement of specific development goals, and royalties on future sales of successfully commercialized products. Aligos also seeks funding from government grants and other sources to support its clinical trials and research initiatives. The company’s financial performance is closely tied to the progress and outcomes of its clinical trials, regulatory approvals, and the commercial success of its developed therapies.

Aligos Therapeutics Financial Statement Overview

Summary

Aligos Therapeutics struggles with profitability, showing ongoing losses and negative cash flows typical for early-stage biotech firms. Despite a robust balance sheet with low leverage, the persistent cash burn and negative profitability metrics are significant risks.

Income Statement

Aligos Therapeutics shows a volatile revenue pattern with a decline to $3.27M in TTM from $15.53M in 2023. Despite improving gross profit margins, ongoing losses with a net profit margin of -1628% in TTM highlight persistent challenges in achieving profitability. The EBIT and EBITDA margins also remain negative, indicating operational inefficiencies.

Balance Sheet

The balance sheet indicates a relatively stable equity position with stockholders' equity at $116.45M, although the negative net income affects ROE. The debt-to-equity ratio of 0.07 suggests low leverage, which is favorable, but the negative equity in previous years is a concern. The equity ratio stands at 77%, reflecting a strong asset base.

Cash Flow

Cash flow analysis reveals negative operating cash flow of -$78.91M, with free cash flow remaining negative at -$79.01M. However, strong financing cash flow at $102.12M in TTM supports liquidity. The operating cash flow to net income ratio shows inefficiency in converting net income to cash, a risk for future operations.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
3.27M	3.94M	15.53M	13.91M	4.36M	0.00
	Gross Profit
1.99M	1.32M	12.46M	10.23M	-99.79M	-3.33M
	EBIT
-86.35M	-89.15M	-88.13M	-97.58M	-128.32M	-97.83M
	EBITDA
-84.50M	-89.15M	-85.06M	-93.91M	-124.54M	-105.06M
	Net Income Common Stockholders
-53.26M	-131.21M	-87.68M	-96.05M	-128.33M	-108.54M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
137.86M	56.94M	135.70M	125.83M	190.73M	243.51M
	Total Assets
150.70M	70.09M	151.53M	146.69M	235.37M	265.30M
	Total Debt
7.87M	8.38M	11.14M	12.57M	14.46M	13.01M
	Net Debt
-65.89M	-28.62M	-124.57M	-68.77M	-172.36M	-207.38M
	Total Liabilities
34.25M	99.07M	59.45M	42.79M	50.64M	45.26M
	Stockholders Equity
116.44M	-28.97M	92.08M	103.90M	184.73M	220.04M
Cash Flow		Free Cash Flow
-79.01M	-80.87M	-79.02M	-80.33M	-116.55M	-76.33M
	Operating Cash Flow
-78.91M	-80.74M	-79.00M	-79.39M	-115.66M	-74.26M
	Investing Cash Flow
26.30M	-18.28M	44.98M	-26.29M	3.02M	32.76M
	Financing Cash Flow
102.12M	355.00K	88.33M	164.00K	78.68M	192.35M

Aligos Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 7.89
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALGS, the sentiment is Neutral. The current price of 7.89 is above the 20-day moving average (MA) of 6.20, above the 50-day MA of 5.60, and below the 200-day MA of 15.70, indicating a neutral trend. The MACD of 0.42 indicates Negative momentum. The RSI at 68.80 is Neutral, neither overbought nor oversold. The STOCH value of 87.64 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ALGS.

Aligos Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TVRD	57 Neutral	$243.85M	―	-414.88%	―	-65.96%	40.80%
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%
ALGS	53 Neutral	$44.64M	―	-60.44%	―	-76.29%	―
GBIO	44 Neutral	$28.50M	―	-70.06%	―	146.47%	57.85%
PYPD	41 Neutral	$35.67M	―	-853.05%	―	―	34.97%
ANVS	35 Underperform	$56.12M	―	-280.78%	―	―	68.75%
NRSN	30 Underperform	$51.10M	―	-2880.11%	―	―	31.09%

Aligos Therapeutics Corporate Events

Aligos Therapeutics Secures $105M in Private Placement

On February 11, 2025, Aligos Therapeutics entered into a Securities Purchase Agreement with investors for a private placement, expected to result in approximately $105 million in gross proceeds. This funding is anticipated to support the advancement of their ALG-000184 into a Phase 2 clinical study and extend the company’s cash runway into the second half of 2026. The private placement, led by a life sciences investment firm, involves the sale of common stock and warrants and is expected to close on February 13, 2025. This financial boost is a strategic move to solidify Aligos’s position in the biotechnology industry focused on liver and viral diseases, providing potential long-term benefits for stakeholders.